Unauthorized domestic export detected; manufacturer moves to control supply chain.
Daewoong Pharmaceutical has announced tighter distribution controls for Nabota following detection of unauthorized exports of domestically-approved product. The move signals supply-chain leakage into gray markets—a recurring challenge for manufacturers with regional regulatory approvals and price differentials across geographies.
Gray-market botulinum toxin typically flows from lower-priced markets (Korea, India) to higher-priced ones (Middle East, Europe, North America), undercutting official distributors and creating liability for practices that unknowingly source compromised product. Daewoong's response—enhanced distributor vetting, serialization, and likely stricter contractual enforcement—is standard but often incomplete without end-user compliance.
Unauthorized Nabota exports detected; manufacturer tightens distribution controls.
For practices sourcing Nabota through legitimate channels, this is largely transparent. But for those considering alternative suppliers or "deals" on toxin pricing, the timing is a reminder: gray-market product carries regulatory, clinical, and legal risk. Daewoong's enforcement signals the company is willing to pursue supply-chain discipline, which typically includes audits of authorized distributors and their end-user sales patterns.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
